Market-View-Feature-Image

View on market: Volatility Prevails, Market is searching for better value

Most Asia-Pacific markets were trading lower in early Tuesday with all eyes on India’s general election results, scheduled to be out later in the day. The Nikkei 225 was 180.62 points, or 0.46% down at 38,742.41, and the KOSPI was 12.99 points, or 0.48% down at 2,669.53 as of 06:23 a.m. After seven phases of polling, the Election Commission is preparing to announce the results of the Lok Sabha 2024 election on Tuesday. With the counting process underway, public sector enterprises, financials, infrastructure, railway and defence will be in focus. US treasuries climbed as a weak manufacturing reading fueled speculation the Federal Reserve will have room to cut interest rates this year, Bloomberg said. The S&P 500 rose 0.11% and the Nasdaq Composite rose 0.56% as of Monday. The Dow Jones Industrial Average fell by 0.30%. Brent crude was trading 0.22% lower at $78.14 a barrel. Gold rose 0.01% to $2,351.02 an ounce.

Economic Calendar:

  • USD : Manufacturing PMI (May) on 03rd June, 2024
  • USD: JOLTs Job Openings (Apr) on 04th June, 2024
  • INR: Nikkei S&P Global Manufacturing PMI (May) on 03rd June, 2024
  • INR: Nikkei Services PMI (May) on 05th June, 2024

Brokerage Radar:

JEFFERIES ON HINDALCO: Buy, TP raised to Rs 810; Novelis’ 4Q EBITDA rose 28% YoY(+13% QoQ) & inline; Vol grew 2% YoY while EBITDA/t rose 8% QoQ to $540, Raise FY25-26E EPS by 2-3%; Vals reasonable at 6.1x FY25E EV/EBITDA

CITI ON MARICO: Buy, TP raised to Rs 610; 4Q In-line; Pricing Action to Drive Growth Expect trajectory to improve in FY25E:

a)vol growth acceleration

b)pricing-led growth

NOMURA ON LUPIN: Buy, TP Rs 1949; 4Q: EBITDA 8% higher than est. Co expects stronger FY25 (vs FY24) driven by growth across key geographies & improvement in EBITDA margins; Think US product launches & a tight leash on costs could present upside potential to current earnings est.

International Markets:

U.S & Europe:

Particulars 03rd June Chg. Chg.(%)
Nasdaq 16828.67 93.65 0.56
Dow 38571.03 -115.29 -0.30
FTSE 8262.75 -12.63 -0.15
CAC 7998.02 5.15 0.06
DAX 18608.16 110.22 0.59
Dow Fut.* 38547.33 -23.70 -0.06

Asian markets:

Particulars 04th June Chg. Chg.(%)
GIFT Nifty 23289.50 -177.50 -0.76
Nikkei 38749.25 -173.78 -0.45
Straits Times 3342.64 -6.23 -0.19
Hang Seng 18480.98 77.94 0.42
Shanghai 3081.55 3.06 0.10

ADR Watch:

Particulars 03rd June  Chg.       Chg.(%)
Dr. Reddy 69.45 0.77 1.12
HDFC Bank 61.23 3.34 5.77
ICICI Bank 28.32 1.58 5.89
Infosys 16.85 0.10 0.60
Wipro 5.27 0.01 2.33

Commodities & Currency:

Particulars Current Price Chg.(%)
USD/INR 83.25 0.18
Brent 77.85 -0.65
Gold 2365.60 -0.16
Silver 30.76 -0.08

FIIs & DIIs:

Particulars 03rd June 31st May
FIIs                          6850.76 1613.24
DIIs 1913.98 2114.17

News Update:

Sectors: The public sector enterprises, financials, infrastructure, railway, and defense will be in focus with the Lok Sabha election results to be announced on Tuesday.

ICICI Bank, Adani Group: The bank and Adani One launched co-branded credit cards with airport-linked benefits. The credit cards are to be rolled out in collaboration with Visa.

Adani Power: The company plans to amalgamate its subsidiary, Mahan Energen, with Stratatech Mineral Resources to enhance fuel security and competitiveness in the power market.

Mahindra and Mahindra: The company reported overall disbursements at Rs 4,430 crore in the month of May, up 7% YoY and business assets at Rs 1.05 lakh crore, up 23% YoY, and collection efficiency stood at 96%.

RVNL: The company received an EPC order worth Rs 440 crore from South Central Railway.

Moil: The company reported manganese ore sales up 41% YoY at 2.15 lakh tonnes.

Zee Entertainment Enterprises: The company board meeting is scheduled for June 6 to consider raising funds by way of the issuance of equity shares.

Biocon: The company received a USFDA nod for the antifungal medication Micafungin. Micafungin is used as an antifungal medication to treat fungal or yeast infections.

Wipro: The company appointed Bruno Schenk as Country Head and Managing Director for Switzerland.

Dr. Reddy’s Laboratories: The company’s arm, Aurigene Pharmaceutical, opens a biologics facility in Hyderabad.

Century Textiles: The company arm incorporated a wholly owned subsidiary, Vibhavya Properties for real estate projects.

Techno Electric: The company has acquired NERES XVI Power Transmission from REC Power Development and Consultancy for Rs 7.15 crore.

Source: Moneycontrol, Bloomberg Quint, Investing 

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and

(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.

For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale.

Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

  1. Reports
  2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;

(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

  1. Compensation

(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;

(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;

(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(d) EWL  or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.